Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Tobramycin dry-powder inhalation - Novartis

Drug Profile

Tobramycin dry-powder inhalation - Novartis

Alternative Names: TBM 100; TIP; TOBI Podhaler; TOBI-TIP; Tobramycin inhalation powder-Novartis

Latest Information Update: 31 May 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Nektar Therapeutics
  • Developer Novartis
  • Class Aminoglycosides; Anti-infectives; Antibacterials; Antibronchitics; Small molecules
  • Mechanism of Action Protein 30S ribosomal subunit inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Cystic fibrosis-associated respiratory tract infections
  • Phase II Bronchiectasis

Most Recent Events

  • 20 Mar 2019 Novartis completes a phase II trial in Bronchiectasis (Adjunctive treatment, Non-cystic fibrosis related) in Italy, Spain, Germany, Ireland, United Kingdom, Belgium, Netherlands, France (Inhalation) (NCT02712983) (EudraCT2015-003040-39)
  • 31 Aug 2018 Tobramycin dry-powder inhalation market licensed to Mylan worldwide
  • 01 Feb 2017 Phase-II clinical trials in Bronchiectasis (Adjunctive treatment, Non-cystic fibrosis related) in Italy, Spain, Germany, Ireland, United Kingdom (Inhalation) (NCT02712983) (EudraCT2015-003040-39)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top